Nano-enabled Peptide Pills

据估计，7000万至1.05亿美国人和约20%的欧洲成年人患有由非恶性(如艾滋病毒、带状疱疹后或糖尿病神经病变、关节炎和下腰痛)和恶性(70%-90%的晚期癌症病例)引起的严重慢性疼痛。目前的治疗方法在75%的慢性非恶性疼痛患者中是不够的，在80%的阿片类药物治疗患者中会导致副作用；副作用包括便秘、恶心、呼吸问题、成瘾和意外过量。2006年，25万名美国患者因止痛药相关并发症需要紧急入院治疗。我们已经开发出一种新的基于纳米药物的止痛药，这种药物在动物实验中有效，无论是口服还是注射都有效。由于我们针对的是一种与传统止痛药不同的受体，预计该药物的副作用较少。我们正在开发的化合物如果不被放入纳米颗粒中就不起作用。

An estimated 70 - 105 million Americans and around 20% of European adults suffer from severe chronic pain caused by non-malignant (e.g., HIV, post-herpetic or diabetic neuropathy, arthritis and lower back pain) and malignant (70%-90% of advanced cancer cases) conditions. Current therapies are inadequate in 75% of cases of chronic non-malignant pain and cause side effects in 80% of opioid treated patients; side effects include constipation, nausea, breathing problems addiction and accidental overdose. In 2006, 250,000 US patients required emergency hospital admission for pain drug related complications. We have developed a new nanomedicine based pain drug which is effective in animal studies and works when taken by mouth or by injection. As we are targeting a different receptor to conventional pain drugs, the drug is predicted to have fewer side effects. The compound we are developing does not work without it being put in nanoparticles.